Beijing Jialuohua Pharmaceutical

Beijing Jialuohua Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Beijing, China, dedicated to the discovery and development of innovative small molecule drugs for autoimmune and inflammatory diseases. The company specializes in the design of highly selective kinase inhibitors, with a particular focus on the Janus kinase (JAK) family to minimize off-target toxicities. Its lead candidate, JLH-1101, is a selective JAK1 inhibitor currently undergoing Phase 2 clinical trials for indications including atopic dermatitis, rheumatoid arthritis, and alopecia areata. Additionally, the company is advancing JLH-1102, a selective JAK3 inhibitor, and JLH-1103, a TYK2 inhibitor, through early-stage clinical development. Jialuohua is backed by prominent investors such as SDIC Unity Capital and aims to address significant unmet medical needs in the immunology space.